Neurocrine Biosciences (NBIX) EBITDA margin US GAAP (year values) |
|||||||||
2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
EBITDA margin, % | ? | 28.8% | 32.1% | 19.3% | 17.8% | 22.0% | 27.6% | ||
Changes by years, y/y, % | +21pp | +3pp | -13pp | -2pp | +4pp | +21.9% |
Neurocrine Biosciences. EBITDA margin, %
Neurocrine Biosciences. EBITDA margin, changes, pp
Neurocrine Biosciences (NBIX) EBITDA margin US GAAP (quarter values) |
||||||||
2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
EBITDA margin, % | ? | 29.4% | 30.3% | 21.6% | 26.3% | 31.6% | 27.6% | |
Changes by years, y/y, % | +6pp | +5pp | +15pp | +10pp | +2pp | |||
Changes by quarters, q/q, % | +13pp | +1pp | -9pp | +5pp | +5pp |